AbCellera Biologics Inc. ABCL Proceeds from long-term liabilities and other
Proceeds from long-term liabilities and other at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:ProceedsFromLiabilitiesAndExerciseOfStockOptions.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s proceeds from long-term liabilities and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s proceeds from long-term liabilities and other?
- AbCellera Biologics Inc. (ABCL) reported proceeds from long-term liabilities and other of $7.43M in Q4 2025.
- How has AbCellera Biologics Inc.'s proceeds from long-term liabilities and other changed year-over-year?
- AbCellera Biologics Inc.'s proceeds from long-term liabilities and other increased by 120.3% year-over-year, from $3.37M to $7.43M.
- What is the long-term trend for AbCellera Biologics Inc.'s proceeds from long-term liabilities and other?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s proceeds from long-term liabilities and other has grown at a 52.6% compound annual growth rate (CAGR), from $5.49M to $29.73M.
- What does proceeds from long-term liabilities and other mean?
- This captures cash inflows from the issuance of long-term debt, other financial liabilities, or the exercise of equity-based instruments. It highlights the company's ability to raise capital through non-operating channels to fund its growth or operational needs. Investors monitor this to evaluate the company's financing strategy and potential dilution or debt burden.